
Which strength training method is best for you? Experts break down the options
When it comes to weight-resistance exercise, you can choose free weights such as dumbbells or barbells. Or weight machines, which are often driven by cables or levers. You can use resistance bands or tubes to build strength. Or try pushups and pullups — old standbys that create muscle overload by using your own body weight.
These four basic options for strength training present fitness possibilities for young or old or beginners. And they offer flexibility for use in the gym, your home or in a hotel room during travel.
You'll probably wind up using a combination of the four, and they all have their pros and cons. They are appropriate for all ages and can be augmented with aerobic exercises like walking or running — or even climbing stairs.
Let's let Dr. Rafael Escamilla, a biomechanist and physical therapist at Sacramento State University in California, and Dr. Michael Stone, a sports scientist at East Tennessee State University, walk us through the possibilities and their pluses and minuses, depending on your age, your motivation and your goals.
Both are internationally recognized experts, college professors and former competitive weightlifters who still work out almost daily. Both suggest a medical check if you're just starting out and the guidance of a trainer at the beginning. Most suggest strength training two or three times per week.
Dumbbells and barbells
We're talking primarily about dumbbells, barbells, kettlebells and medicine balls.
'If you're relatively healthy, free weights are the way to go,' Stone told The Associated Press. 'They have more carryover to daily life — to lifting things. It transfers better. In daily life you pick up your grandchildren, pick up the groceries.'
Free weights are also more versatile, accommodating natural movements that a machine will not allow. Free weights require the user to focus on balance, activating additional muscle groups than simply those targeted.
Stone reminded that you need not use much weight. Just a pound, or a kilo or two, will do it. Start slowly and increase the weight gradually.
'I would also strongly suggest that if you've never lifted weights before, go find somebody who knows something about it,' Stone added.
Weight machines
This is probably the least intimidating option for the beginner. The machines offer stability and a fixed pattern of movement and they give beginners a chance to get familiar with the movements involved in strength training.
'Machines are a good way to start,' Escamilla told The Associated Press. 'They're safe and easy and you don't need a lot of technique or skill to do them.'
Escamilla pointed out they also reduce the risk of injury, isolate muscles and help build confidence as you're starting out. The machines also are more time effective.
'Start here and then you can gravitate to free weight and other options,' Escamilla said.
Resistance bands and tubes
These are the most portable options. They can help to build muscle, improve flexibility and balance, and avoid the need to sign up for a gym membership. The bands or tubes are made of elastic and come in a variety of sizes and resistance levels — how far they stretch and how difficult it is to stretch them.
Bands also come in fabric models.
'They take up no room to pack and they're supercheap,' Escamilla said. 'You can take them with you as you travel — just throw them in your suitcase.'
You can use them to work your legs, arms, back, chest and shoulders and other muscle groups. They can be used in many configurations and may be less intimidating than dumbbells or barbells.
'The bands won't cut it for a 300-pound (140-kilo) football player,' Escamilla added. 'But they're good for your average person — your average adult.'
Bodyweight resistance
The idea with every weight-resistance exercise is to overload the muscles. Your own bodyweight can be used to do this.
Exercises like pushups, pullups, squats, lunges and planks and others fall into this category.
'Your body weight can be used as a form of resistance,' Escamilla said. 'You can get a good workout doing these and you need almost no equipment.'
No matter the option, Stone emphasized the need to vary your exercises — both the types and the number of repetitions. You can also vary locations, perhaps choosing an outdoor gym for your workouts.
Outdoor gyms are often found on beaches like the one at the popular Barceloneta beach in Barcelona, Spain.
'You can't do the same number of sets and repetitions all the time and expect to get better results,' Stone said. 'You get stale and monotony can set in.'
Stephen Wade, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
11 hours ago
- CBC
Justin Timberlake reveals 'debilitating' Lyme disease diagnosis as he wraps world tour
American singer Justin Timberlake says he has been diagnosed with Lyme disease and has been coping with health issues that have affected him physically and mentally. "Living with this can be relentlessly debilitating," he said in a lengthy message to fans posted to Instagram on Wednesday. The 44-year old said he wanted to "shed some light about what he's been up against behind the scenes" on his The Forget Tomorrow World Tour, which began on April 29, 2024, in Vancouver and wrapped up in Istanbul on Tuesday. Fans had recently criticized Timberlake for low-energy performances at recent concerts in Europe. He said that he had dealt with a "massive amount of nerve pain" or at times felt "crazy fatigue or sickness" while on stage during the tour. Lyme disease is caused by a bacterial infection that is usually the result of of a tick bite. The illness progresses in stages. According to the Public Health Agency of Canada, early signs of the illness can include fever, fatigue and muscle and joint aches, while later-stage symptoms can include pain in bones and nerves, weakness, tingling or loss of sensation in limbs, swelling of the brain and spinal cord, memory loss and the inability to think clearly. "I was faced with a personal decision. Stop touring? Or, keep going and figure it out," he wrote. "I decided the joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going." The former member of the boy band NSYNC thanked his fans for supporting him on his most recent tour and throughout the years. "Your energy and love continues to humble me," he said. The SexyBack and Mirrors singer said he's generally a private person and was "reluctant" to speak about his health conditions but that he's "trying to be more transparent about my struggles so that they aren't misinterpreted." He added that he wants to do his part to help others living with the disease. Tick-borne illnesses are on the rise. Here's what to look out for 22 days ago Dr. Samir Gupta, a Toronto-based respirologist, is warning of an increase in tick bites and tick-borne illnesses across Canada. Ticks are parasites that feed on the blood of wild animals and are known to transmit bacteria through bites.


CTV News
14 hours ago
- CTV News
Moderna plans to lay off 10% of workforce to cut costs
In this file photo dated Wednesday, Feb. 17, 2021, three vials of the Moderna COVID-19 Vaccine are pictured in a new coronavirus vaccination centre in Berlin, Germany. (AP Photo/Michael Sohn, File) Moderna said on Thursday it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines. The move, announced in an internal memo by CEO Stephane Bancel, is part of the company's previous plan to cut operating expenses by about US$1.5 billion by 2027. 'We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs,' Bancel said in the memo. Moderna had said earlier this year it expects operating costs to be between US$4.7 billion and US$5 billion for 2027. The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine. But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20 per cent decline in Moderna's shares this year. The stock, which has lost more than 90 per cent of its value since the pandemic-era highs, was trading about four per cent down on Thursday. Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu. The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years. --- Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar

National Post
20 hours ago
- National Post
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
Article content Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies Article content SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. Article content 'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.' Article content In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Article content The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need. Article content The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster. Article content About BGB-16673 Article content BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program. Article content About BeOne Medicines Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Article content Forward-Looking Statement Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Contacts Article content Investor Contact Article content Article content Liza Heapes Article content Article content +1 857-302-5663 Article content Article content ir@ Article content Media Contact Article content Article content Kyle Blankenship Article content Article content Article content